The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Open accessAbstract
Purpose: Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC. Patients and Methods: Tumors were tested for AR with an immunohistochemistry assay optimized for breast cancer; nuclear AR staining > 0% was considered positive. Patients received enzalutamide 160 mg once per day until disease progression. The primary end point was clinical benefit rate (CBR) at 16 weeks. Secondary end points included CBR at 24 weeks, progression-free survival, and safety. End points were analyzed in all enrolled patients (the intent-to-treat [ITT] population) and in patients with one or more postbaseline assessment whose tumor expressed ≥ 10% nuclear AR (the evaluable subgroup). Results: Of 118 patients enrolled, 78 were evaluable. CBR at 16 weeks was 25% (95% CI, 17% to 33%) in the ITT population and 33% (95% CI, 23% to 45%) in the evaluable subgroup. Median progression-free survival was 2.9 months (95% CI, 1.9 to 3.7 months) in the ITT population and 3.3 months (95% CI, 1.9 to 4.1 months) in the evaluable subgroup. Median overall survival was 12.7 months (95% CI, 8.5 months to not yet reached) in the ITT population and 17.6 months (95% CI, 11.6 months to not yet reached) in the evaluable subgroup. Fatigue was the only treatment-related grade 3 or higher adverse event with an incidence of > 2%. Conclusion: Enzalutamide demonstrated clinical activity and was well tolerated in patients with advanced AR-positive TNBC. Adverse events related to enzalutamide were consistent with its known safety profile. This study supports additional development of enzalutamide in advanced TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationElkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Self-citationEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Self-citationA Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Self-citationIdentification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208561 · Cited by 785
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Self-citationDoane, A. S., Danso, M., Lal, P., Donaton, M., Zhang, L., Hudis, C., & Gerald, W. L. (2006) · Oncogene · doi:10.1038/sj.onc.1209415 · Cited by 603
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., Brunet, J.-S., Akslen, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2132 · Cited by 489
Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 481
Thomas, E. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5019 · Cited by 428
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., Spoelstra, N. S., Edgerton, S. M., Jean, A., Guerrero, J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3599 · Cited by 427
Brufsky, A. M., Hurvitz, S., Perez, E., Swamy, R., Valero, V., O'Neill, V., & Rugo, H. S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1255 · Cited by 421
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities
Sørlie, T. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.08.021 · Cited by 415
Collins, L. C., Cole, K. S., Marotti, J. D., Hu, R., Schnitt, S. J., & Tamimi, R. M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.54 · Cited by 387
Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2408 · Cited by 363
Self-citationNew Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity
Mayer, I. A., Abramson, V. G., Lehmann, B. D., & Pietenpol, J. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0583 · Cited by 320
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
Penson, D. F., Armstrong, A. J., Concepcion, R., Agarwal, N., Olsson, C., Karsh, L., Dunshee, C., Wang, F., Wu, K., Krivoshik, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.9285 · Cited by 319
Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
Shore, N. D., Chowdhury, S., Villers, A., Klotz, L., Siemens, D. R., Phung, D., van Os, S., Hasabou, N., Wang, F., Bhattacharya, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00518-5 · Cited by 278
Chacón, R. D., & Costanzo, M. V. (2010) · Breast Cancer Research · doi:10.1186/bcr2574 · Cited by 239
Pattern of metastasis and outcome in patients with breast cancer
Gerratana, L., Fanotto, V., Bonotto, M., Bolzonello, S., Minisini, A. M., Fasola, G., & Puglisi, F. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9697-2 · Cited by 218
Twelves, C., Cortes, J., Vahdat, L., Olivo, M., He, Y., Kaufman, P. A., & Awada, A. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3144-y · Cited by 217
Self-citationLoibl, S., Müller, B. M., von Minckwitz, G., Schwabe, M., Roller, M., Darb-Esfahani, S., Ataseven, B., du Bois, A., Fissler-Eckhoff, A., Gerber, B., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1715-8 · Cited by 211
Impact of breast cancer subtypes and patterns of metastasis on outcome
Kast, K., Link, T., Friedrich, K., Petzold, A., Niedostatek, A., Schoffer, O., Werner, C., Klug, S. J., Werner, A., Gatzweiler, A., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3341-3 · Cited by 209
von Minckwitz, G., Puglisi, F., Cortés, J., Vrdoljak, E., Marschner, N. W., Zielinski, C. C., Villanueva, C., Romieu, G., Láng, I., Ciruelos, E., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70439-5 · Cited by 143
Brufsky, A., Valero, V., Tiangco, B., Dakhil, S. R., Brize, A., Rugo, H. S., Rivera, R., Duenne, A., Bousfoul, N., & Yardley, D. A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2008-6 · Cited by 137
Self-citationAndrogen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?
Safarpour, D., Pakneshan, S., & Tavassoli, F. A. (2014) · Europe PMC (PubMed Central) · Cited by 97
O’Shaughnessy, J., Campone, M., Brain, E. G. C., Neven, P., Hayes, D. F., Bondarenko, I., Griffin, T. W., Martin, J., Porre, P. D., Kheoh, T. S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv487 · Cited by 66
Self-citationKumar, V., Yu, J., Phan, V. T., Tudor, I. C., Peterson, A., & Uppal, H. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00075 · Cited by 42
Self-citation
Cited by
Triple-negative breast cancer molecular subtyping and treatment progress
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,452
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationGarrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citation
Metadata
- Authors
- Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., Nanda, R., Gucalp, A., Awada, A., Garcia-Estevez, L., Trudeau, M. E., Steinberg, J., Uppal, H., Tudor, I. C., Peterson, A., & Cortes, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-03-20
- Volume
- 36
- Issue
- 9
- Pages
- 884-890
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2784775153
- Cited by
- 530
- References
- 34
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.